FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2975259471> ?p ?o ?g. }

• W2975259471 endingPage "3396" @default.
• W2975259471 startingPage "3396" @default.
• W2975259471 abstract "Introduction: The NCCN guidelines have recently been updated to include recommendations on tyrosine kinase inhibitor (TKI) therapy discontinuation for patients with chronic myeloid leukemia in chronic phase (CML-CP). A recent physician survey on TKI therapy discontinuation practice showed that before publication of the NCCN recommendations, conditions under which physicians would consider TKI therapy discontinuation differed from these recommendations and may have resulted in discontinuation where deep response was not achieved and disease not adequately monitored (Ritchie, ASCO 2017). This study further assessed TKI therapy treatment patterns, using real-world patient-level data, with a focus on TKI therapy discontinuation. Methods: Patient-level data were abstracted from charts and collected via an online questionnaire, which was completed by US oncologists/hematologists between June 6 and July 28, 2017. Data were collected for adult patients diagnosed with CML-CP who were initiated on a TKI as first-line therapy, not as part of an interventional clinical trial, between January 2006 and March 2014. Patient demographics, clinical and treatment characteristics, and treatment patterns with a focus on TKI therapy discontinuation were described. All statistical analyses were descriptive. Results: Data were abstracted on 732 patients with CML-CP by 123 physicians. Patients were on average 56 years old, 60% were male, and 8% had an ECOG ≥ 2. Most patients (447; 61%) received imatinib (403 [90% of 447] had 400 mg QD; 29 [6%] had 600 mg QD as the initial dose) as first line therapy, 180 (25%) received dasatinib (126 [70% of 180] had 100 mg QD; 43 [24%] had 50mg BID as the initial dose), and 105 (14%) received nilotinib (51 [49% of 105] had 300 mg BID; 41 [39%] had 400 mg QD as the initial dose). Over an average observation period of 4.8 years from first-line TKI initiation, 598 (82%) patients were observed to remain on first-line therapy without interruptions, 82 (11%) patients switched directly to another treatment for CML (main reasons included loss of molecular response [37% of 82]; failure to achieve satisfactory response/resistance [30%]; and adverse event [18%]), 29 (4%) patients interrupted the treatment and restarted the same treatment (main reasons included adverse events [34% of 29]; the patient no longer wanted to take the medication/patient9s anxiety [28%]; and economic reason [14%]), and 23 (3%) patients discontinued all CML therapy. See Table 1. In total, TKI therapy was discontinued in 25 of the 732 patients (3.4%) after they achieved an adequate response, with the intention to remain free of CML pharmacological therapy until disease relapse. Among these 25 patients, the main reasons for discontinuation included: the patient achieved an adequate response (40% of 25), the patient no longer wanted to take the medication/patient9s anxiety (20%), adverse events (20%), and pregnancy or planning to become pregnant (12%). Before discontinuation, 52% of these 25 patients achieved undetectable BCR-ABL response, 20% a decrease in BCR-ABL of ≥4.5 log, 20% a 4 log reduction, and 4% a 3 log reduction. A proportion of 20% (of 25) patients maintained the response for 3 years before discontinuation, 24% 2 years, 24% 1 year, and 20% 6 months. A proportion of 52% (of 25) of patients had been on TKI therapy for ≥3 years before discontinuation, 16% 2 years, 16% 1 year, and 16% Conclusion: In this real-world study of 732 patients who started first-line TKI therapy for CML-CP between 2006 and 2014, TKI therapy discontinuation was attempted for 3.4% of patients who achieved an adequate response with the intention to remain free of CML pharmacological therapy until disease relapse, mainly before the release of NCCN recommendations on TKI therapy discontinuation. The findings also suggest a more conservative TKI therapy discontinuation practice versus that previously reported in the physician survey. Further studies are warranted to understand whether this trend would change following the communication and increased awareness of the new TKI therapy discontinuation guidelines. Disclosures Ritchie: Novartis: Consultancy, Other: Research funding to my institution, and travel, Speakers Bureau; Bristol-Myers Squibb: Other: Research funding to my institution; Astellas Pharma: Other: Research funding to my institution; NS Pharma: Other: Research funding to my institution; Incyte: Consultancy, Speakers Bureau; Celgene: Consultancy, Other: Travel, Speakers Bureau; Pfizer: Consultancy, Other: Research funding to my institution. Latremouille-Viau: Novartis: Other: Analysis Group, Inc. has received consulting fees from Novartis; Analysis Group, Inc.: Employment. Guerin: Analysis Group, Inc: Employment; AbbVie Inc.: Other: I am an employee of Analysis Group, which received consulting fees from AbbVie ; Novartis: Other: I am an employee of Analysis Group, which received consulting fees from Novartis. Pivneva: Analysis Group, Inc: Employment; Novartis: Other: Analysis Group, Inc. has received consulting fees from Novartis. Habucky: Novartis: Employment. Ndife: Novartis Pharmaceuticals Corporation: Employment. Joseph: Novartis Pharmaceuticals Corporation: Employment; Pfizer: Other: stock/stock options; Amgen: Other: stock/stock options; Express Scripts: Other: stock/stock options. Atallah: ADC Therapeutics: Research Funding." @default.
• W2975259471 created "2019-10-03" @default.
• W2975259471 creator A5004070569 @default.
• W2975259471 creator A5041026389 @default.
• W2975259471 creator A5050220593 @default.
• W2975259471 creator A5058741297 @default.
• W2975259471 creator A5059264128 @default.
• W2975259471 creator A5074297763 @default.
• W2975259471 creator A5078887304 @default.
• W2975259471 creator A5085492465 @default.
• W2975259471 date "2017-12-07" @default.
• W2975259471 modified "2023-09-26" @default.
• W2975259471 title "Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation" @default.
• W2975259471 hasPublicationYear "2017" @default.
• W2975259471 type Work @default.
• W2975259471 sameAs 2975259471 @default.
• W2975259471 citedByCount "0" @default.
• W2975259471 crossrefType "journal-article" @default.
• W2975259471 hasAuthorship W2975259471A5004070569 @default.
• W2975259471 hasAuthorship W2975259471A5041026389 @default.
• W2975259471 hasAuthorship W2975259471A5050220593 @default.
• W2975259471 hasAuthorship W2975259471A5058741297 @default.
• W2975259471 hasAuthorship W2975259471A5059264128 @default.
• W2975259471 hasAuthorship W2975259471A5074297763 @default.
• W2975259471 hasAuthorship W2975259471A5078887304 @default.
• W2975259471 hasAuthorship W2975259471A5085492465 @default.
• W2975259471 hasConcept C121608353 @default.
• W2975259471 hasConcept C126322002 @default.
• W2975259471 hasConcept C187212893 @default.
• W2975259471 hasConcept C2777413986 @default.
• W2975259471 hasConcept C2777583451 @default.
• W2975259471 hasConcept C2778715236 @default.
• W2975259471 hasConcept C2778729363 @default.
• W2975259471 hasConcept C2778820342 @default.
• W2975259471 hasConcept C2779536868 @default.
• W2975259471 hasConcept C3019892230 @default.
• W2975259471 hasConcept C535046627 @default.
• W2975259471 hasConcept C71924100 @default.
• W2975259471 hasConceptScore W2975259471C121608353 @default.
• W2975259471 hasConceptScore W2975259471C126322002 @default.
• W2975259471 hasConceptScore W2975259471C187212893 @default.
• W2975259471 hasConceptScore W2975259471C2777413986 @default.
• W2975259471 hasConceptScore W2975259471C2777583451 @default.
• W2975259471 hasConceptScore W2975259471C2778715236 @default.
• W2975259471 hasConceptScore W2975259471C2778729363 @default.
• W2975259471 hasConceptScore W2975259471C2778820342 @default.
• W2975259471 hasConceptScore W2975259471C2779536868 @default.
• W2975259471 hasConceptScore W2975259471C3019892230 @default.
• W2975259471 hasConceptScore W2975259471C535046627 @default.
• W2975259471 hasConceptScore W2975259471C71924100 @default.
• W2975259471 hasLocation W29752594711 @default.
• W2975259471 hasOpenAccess W2975259471 @default.
• W2975259471 hasPrimaryLocation W29752594711 @default.
• W2975259471 hasRelatedWork W2520303690 @default.
• W2975259471 hasRelatedWork W2552088583 @default.
• W2975259471 hasRelatedWork W2553772967 @default.
• W2975259471 hasRelatedWork W2554924700 @default.
• W2975259471 hasRelatedWork W2588965196 @default.
• W2975259471 hasRelatedWork W2589223902 @default.
• W2975259471 hasRelatedWork W2601192207 @default.
• W2975259471 hasRelatedWork W2782783975 @default.
• W2975259471 hasRelatedWork W2785636942 @default.
• W2975259471 hasRelatedWork W2979508330 @default.
• W2975259471 hasRelatedWork W2979511046 @default.
• W2975259471 hasRelatedWork W2980044124 @default.
• W2975259471 hasRelatedWork W3000089230 @default.
• W2975259471 hasRelatedWork W3094674409 @default.
• W2975259471 hasRelatedWork W3095543762 @default.
• W2975259471 hasRelatedWork W3097094448 @default.
• W2975259471 hasRelatedWork W3111008834 @default.
• W2975259471 hasRelatedWork W3112379566 @default.
• W2975259471 hasRelatedWork W3135587612 @default.
• W2975259471 hasRelatedWork W3198263467 @default.
• W2975259471 hasVolume "130" @default.
• W2975259471 isParatext "false" @default.
• W2975259471 isRetracted "false" @default.
• W2975259471 magId "2975259471" @default.
• W2975259471 workType "article" @default.